CN101370792B - 激酶的联-芳基间-嘧啶抑制剂 - Google Patents

激酶的联-芳基间-嘧啶抑制剂 Download PDF

Info

Publication number: CN101370792B
Authority: CN; China
Prior art keywords: compound; mixture; methyl; unsubstituted; alkyl
Prior art date: 2005-11-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CN200680049966.8A

Other languages

English (en)

Chinese (zh)

Other versions

CN101370792A (zh

Inventor

J·J·曹

J·胡德

D·罗赫塞

C·C·梅克

A·麦克菲尔森

G·诺龙哈

V·派特哈克

J·雷尼克

R·M·索尔

曾斌琦

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Biomedical impact company

Original Assignee

TargeGen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-01

Filing date

2006-10-26

Publication date

2013-03-20

2006-10-26 Application filed by TargeGen Inc filed Critical TargeGen Inc

2006-10-26 Priority to CN201310043377.0A priority Critical patent/CN103626742B/zh

2006-10-26 Priority claimed from PCT/US2006/042044 external-priority patent/WO2007053452A1/en

2009-02-18 Publication of CN101370792A publication Critical patent/CN101370792A/zh

2013-03-20 Application granted granted Critical

2013-03-20 Publication of CN101370792B publication Critical patent/CN101370792B/zh

Status Active legal-status Critical Current

2026-10-26 Anticipated expiration legal-status Critical

Links

KZNGQPRTNBSQSW-UHFFFAOYSA-N Cc1cnc(Nc(cc2)ccc2OCCN2CCCC2)nc1Nc1ccc2OCOc2c1 Chemical compound Cc1cnc(Nc(cc2)ccc2OCCN2CCCC2)nc1Nc1ccc2OCOc2c1 KZNGQPRTNBSQSW-UHFFFAOYSA-N 0.000 description 2
YGJCGMPXGMXJNJ-UHFFFAOYSA-N CC(C)(C)NC(c1cc(Nc2c(C)cnc(Nc(cc3)ccc3N3CCN(C)CC3)n2)ccc1)=O Chemical compound CC(C)(C)NC(c1cc(Nc2c(C)cnc(Nc(cc3)ccc3N3CCN(C)CC3)n2)ccc1)=O YGJCGMPXGMXJNJ-UHFFFAOYSA-N 0.000 description 1
IAXMYIMAOOVYIT-UHFFFAOYSA-N CC(C)(C)NS(c1cc(Nc2c(C)cnc(Nc(cc3)cc(C(F)(F)F)c3N(CC3)CCN3C(C)=O)n2)ccc1)(=O)=O Chemical compound CC(C)(C)NS(c1cc(Nc2c(C)cnc(Nc(cc3)cc(C(F)(F)F)c3N(CC3)CCN3C(C)=O)n2)ccc1)(=O)=O IAXMYIMAOOVYIT-UHFFFAOYSA-N 0.000 description 1
JVDOKQYTTYUYDV-UHFFFAOYSA-N CC(C)(C)NS(c1cc(Nc2c(C)cnc(Nc(cc3)ccc3N3CCN(C)CC3)n2)ccc1)(=O)=O Chemical compound CC(C)(C)NS(c1cc(Nc2c(C)cnc(Nc(cc3)ccc3N3CCN(C)CC3)n2)ccc1)(=O)=O JVDOKQYTTYUYDV-UHFFFAOYSA-N 0.000 description 1
DYCXXZIMXKKAHO-UHFFFAOYSA-N CC(C)(C)NS(c1cc(Nc2c(C)cnc(Nc3cc(N4CCN(CCO)CC4)ccc3)n2)ccc1)(=O)=O Chemical compound CC(C)(C)NS(c1cc(Nc2c(C)cnc(Nc3cc(N4CCN(CCO)CC4)ccc3)n2)ccc1)(=O)=O DYCXXZIMXKKAHO-UHFFFAOYSA-N 0.000 description 1
NJQSBJYFLMVOQI-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1Oc(cc1)ccc1Nc1nc(Nc2cccc(OC)c2)c(C)cn1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1Oc(cc1)ccc1Nc1nc(Nc2cccc(OC)c2)c(C)cn1)=O NJQSBJYFLMVOQI-UHFFFAOYSA-N 0.000 description 1
YRLQFRXDWBFGMK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1c(cc1)ccc1N)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1c(cc1)ccc1N)=O YRLQFRXDWBFGMK-UHFFFAOYSA-N 0.000 description 1
ALKVLJPJNKSFIE-UHFFFAOYSA-N CC(C)(C)OC(N1CCN(Cc2cc(Nc3nc(Nc(cc4OC)ccc4Cl)c(C)cn3)ccc2)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(Cc2cc(Nc3nc(Nc(cc4OC)ccc4Cl)c(C)cn3)ccc2)CC1)=O ALKVLJPJNKSFIE-UHFFFAOYSA-N 0.000 description 1
AKEHJPURDMAKTF-UHFFFAOYSA-N CC(Nc1cccc(Nc2nc(Nc(cc3)ccc3OC3CCNCC3)ncc2C)c1)=O Chemical compound CC(Nc1cccc(Nc2nc(Nc(cc3)ccc3OC3CCNCC3)ncc2C)c1)=O AKEHJPURDMAKTF-UHFFFAOYSA-N 0.000 description 1
QLMJKZVSIFCPGU-UHFFFAOYSA-N CC1C2C1CCCC2 Chemical compound CC1C2C1CCCC2 QLMJKZVSIFCPGU-UHFFFAOYSA-N 0.000 description 1
FKPWJXRTAOUEED-UHFFFAOYSA-N CCc1cc(Nc2c(C)cnc(Nc(cc3)ccc3-[n]3c(C)ncc3)n2)ccc1 Chemical compound CCc1cc(Nc2c(C)cnc(Nc(cc3)ccc3-[n]3c(C)ncc3)n2)ccc1 FKPWJXRTAOUEED-UHFFFAOYSA-N 0.000 description 1
MNATXMOMEVYVPO-UHFFFAOYSA-N Cc(c(Nc(cc1Cl)ccc1C#N)n1)cnc1Cl Chemical compound Cc(c(Nc(cc1Cl)ccc1C#N)n1)cnc1Cl MNATXMOMEVYVPO-UHFFFAOYSA-N 0.000 description 1
SNMYDIJTWFXHQL-UHFFFAOYSA-N Cc(c(Nc(cc1OC)ccc1F)n1)cnc1Cl Chemical compound Cc(c(Nc(cc1OC)ccc1F)n1)cnc1Cl SNMYDIJTWFXHQL-UHFFFAOYSA-N 0.000 description 1
OEOMRXZYYISPRB-UHFFFAOYSA-N Cc(c(Nc1ccc2OCOc2c1)n1)cnc1Cl Chemical compound Cc(c(Nc1ccc2OCOc2c1)n1)cnc1Cl OEOMRXZYYISPRB-UHFFFAOYSA-N 0.000 description 1
JENUZEJOBDHTGZ-UHFFFAOYSA-N Cc(c(Nc1ccnc(Nc(cc2)ccc2OCCN2CCCC2)n1)ccc1)c1OC Chemical compound Cc(c(Nc1ccnc(Nc(cc2)ccc2OCCN2CCCC2)n1)ccc1)c1OC JENUZEJOBDHTGZ-UHFFFAOYSA-N 0.000 description 1
YOURZEAULAHBOK-UHFFFAOYSA-N Cc1c(Nc(cc2)cc(Cl)c2Cl)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 Chemical compound Cc1c(Nc(cc2)cc(Cl)c2Cl)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 YOURZEAULAHBOK-UHFFFAOYSA-N 0.000 description 1
HXKIWXBIBASZSX-UHFFFAOYSA-N Cc1c(Nc(cc2)ccc2Cl)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 Chemical compound Cc1c(Nc(cc2)ccc2Cl)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 HXKIWXBIBASZSX-UHFFFAOYSA-N 0.000 description 1
XXVCIDLHARIYBR-UHFFFAOYSA-N Cc1c(Nc2c3OCOc3ccc2)nc(Nc(cc2)cc(OC)c2OCCN2CCCC2)nc1 Chemical compound Cc1c(Nc2c3OCOc3ccc2)nc(Nc(cc2)cc(OC)c2OCCN2CCCC2)nc1 XXVCIDLHARIYBR-UHFFFAOYSA-N 0.000 description 1
OVHJQWAMVNBHMN-UHFFFAOYSA-N Cc1c(Nc2cc(S(N3CCCCC3)(=O)=O)ccc2)nc(Nc(cc2)ccc2N2CCN(C)CC2)nc1 Chemical compound Cc1c(Nc2cc(S(N3CCCCC3)(=O)=O)ccc2)nc(Nc(cc2)ccc2N2CCN(C)CC2)nc1 OVHJQWAMVNBHMN-UHFFFAOYSA-N 0.000 description 1
DGVSHUWXUMASQD-UHFFFAOYSA-N Cc1c(Nc2cccc(N(C)C)c2)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 Chemical compound Cc1c(Nc2cccc(N(C)C)c2)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 DGVSHUWXUMASQD-UHFFFAOYSA-N 0.000 description 1
FDQGULQDRHCMJB-UHFFFAOYSA-N Cc1c(Nc2cccc(NC(Nc3ccccc3)=O)c2)nc(Nc(cc2)ccc2N2CCN(C)CC2)nc1 Chemical compound Cc1c(Nc2cccc(NC(Nc3ccccc3)=O)c2)nc(Nc(cc2)ccc2N2CCN(C)CC2)nc1 FDQGULQDRHCMJB-UHFFFAOYSA-N 0.000 description 1
BIWRWICMBCFTTH-UHFFFAOYSA-N Cc1c(Nc2cccc(O)c2)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 Chemical compound Cc1c(Nc2cccc(O)c2)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 BIWRWICMBCFTTH-UHFFFAOYSA-N 0.000 description 1
AFHORLYEFHIBRF-UHFFFAOYSA-N Cc1c(Nc2ccccc2)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 Chemical compound Cc1c(Nc2ccccc2)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 AFHORLYEFHIBRF-UHFFFAOYSA-N 0.000 description 1
KANQFSODIOGWMX-UHFFFAOYSA-N Cc1c(Nc2nccc3c2cccc3)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 Chemical compound Cc1c(Nc2nccc3c2cccc3)nc(Nc(cc2)ccc2OCCN2CCCC2)nc1 KANQFSODIOGWMX-UHFFFAOYSA-N 0.000 description 1
UFXKSLLMDUESTM-UHFFFAOYSA-N Cc1cc(C)cc(Nc2c(C)cnc(Nc(cc3)ccc3OC3CCNCC3)n2)c1 Chemical compound Cc1cc(C)cc(Nc2c(C)cnc(Nc(cc3)ccc3OC3CCNCC3)n2)c1 UFXKSLLMDUESTM-UHFFFAOYSA-N 0.000 description 1
PJTDJVRVEAMPGJ-UHFFFAOYSA-N Cc1cc(Nc2c(C)cnc(Nc(cc3)ccc3OC3CCNCC3)n2)ccc1Cl Chemical compound Cc1cc(Nc2c(C)cnc(Nc(cc3)ccc3OC3CCNCC3)n2)ccc1Cl PJTDJVRVEAMPGJ-UHFFFAOYSA-N 0.000 description 1
HZYKTMNELNYUID-UHFFFAOYSA-N Cc1cnc(Nc(cc2)ccc2N2CCN(C)CC2)nc1Nc1cccc(S(N2CCCC2)(=O)=O)c1 Chemical compound Cc1cnc(Nc(cc2)ccc2N2CCN(C)CC2)nc1Nc1cccc(S(N2CCCC2)(=O)=O)c1 HZYKTMNELNYUID-UHFFFAOYSA-N 0.000 description 1
PNZZQMNVMMFWHW-UHFFFAOYSA-N OCCN(CC1)CCC1c1cc(Br)ccc1 Chemical compound OCCN(CC1)CCC1c1cc(Br)ccc1 PNZZQMNVMMFWHW-UHFFFAOYSA-N 0.000 description 1

CN200680049966.8A 2005-11-01 2006-10-26 激酶的联-芳基间-嘧啶抑制剂 Active CN101370792B (zh)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CN201310043377.0A CN103626742B (zh)	2005-11-01	2006-10-26	激酶的联-芳基间-嘧啶抑制剂

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US73262905P	2005-11-01	2005-11-01
US60/732,629		2005-11-01
US83800306P	2006-08-15	2006-08-15
US60/838,003		2006-08-15
PCT/US2006/042044 WO2007053452A1 (en)	2005-11-01	2006-10-26	Bi-aryl meta-pyrimidine inhibitors of kinases

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201310043377.0A Division CN103626742B (zh)	2005-11-01	2006-10-26	激酶的联-芳基间-嘧啶抑制剂

Publications (2)

Publication Number	Publication Date
CN101370792A CN101370792A (zh)	2009-02-18
CN101370792B true CN101370792B (zh)	2013-03-20

Family

ID=40413957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN200680049966.8A Active CN101370792B (zh)	2005-11-01	2006-10-26	激酶的联-芳基间-嘧啶抑制剂

Country Status (3)

Country	Link
CN (1)	CN101370792B (xx)
UA (3)	UA109411C2 (xx)
ZA (1)	ZA200804083B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20120114355A (ko) *	2010-01-13	2012-10-16	글락소스미스클라인 엘엘씨	화합물 및 방법
WO2012060847A1 (en) *	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
CN103242240B (zh) *	2012-02-10	2016-01-06	上海温康化学研发有限公司	一种磺酰胺类化合物的中间体、其盐及其制备方法
CN105796562A (zh) *	2012-09-10	2016-07-27	杨子娇	化合物在制备防治青光眼病的药物中的用途
CN103664798A (zh) *	2012-09-20	2014-03-26	杨育新	一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664799A (zh) *	2012-09-25	2014-03-26	杨子娇	一类治疗房角狭窄的化合物及其用途
CN103664907A (zh) *	2012-09-25	2014-03-26	杨子娇	一类治疗房角狭窄的化合物及其用途
CN103724331A (zh) *	2012-10-11	2014-04-16	韩冰	一类治疗脑性瘫痪的化合物及其用途
EP2970205B1 (en) *	2013-03-14	2019-05-08	Tolero Pharmaceuticals, Inc.	Jak2 and alk2 inhibitors and methods for their use
RS57662B1 (sr) *	2013-12-11	2018-11-30	Biogen Ma Inc	Biaril jedinjenja korisna za lečenje humanih bolesti u onkologiji, neurologiji i imunologiji
CN103992262B (zh) *	2014-06-12	2015-11-11	苏州明锐医药科技有限公司	塞瑞替尼及其中间体的制备方法
CN106188063A (zh) *	2015-05-08	2016-12-07	中国科学院上海药物研究所	用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
CN108689949A (zh) *	2018-07-02	2018-10-23	湖南华腾制药有限公司	一种嘧啶类衍生物及其制备方法
CN110305140B (zh)	2019-07-30	2020-08-04	上海勋和医药科技有限公司	二氢吡咯并嘧啶类选择性jak2抑制剂
US20220402948A1 (en) *	2019-09-26	2022-12-22	Betta Pharmaceuticals Co., Ltd.	Egfr inhibitor, composition and preparation method therefor
US20240108633A1 (en) *	2020-12-29	2024-04-04	Onquality Pharmaceuticals China Ltd.	Method for preventing or treating disease or condition associated with antitumor agent
AU2021416682B2 (en) *	2021-01-11	2024-01-11	Guangzhou Salustier Biosciences Co., Ltd.	2-aminopyrimidine compound and pharmaceutical composition thereof and application thereof
CN112920124B (zh) *	2021-01-29	2024-03-01	安徽医科大学	一种嘧啶-2,4-二胺类化合物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1416423A (zh) *	2000-03-01	2003-05-07	阿斯特拉曾尼卡有限公司	用作抗肿瘤剂的2,4－二(杂－)芳基氨基(－氧基)－5－取代的嘧啶

2006
- 2006-10-26 UA UAA201203127A patent/UA109411C2/uk unknown
- 2006-10-26 ZA ZA200804083A patent/ZA200804083B/xx unknown
- 2006-10-26 UA UAA201203128A patent/UA109412C2/uk unknown
- 2006-10-26 UA UAA200807479A patent/UA99899C2/ru unknown
- 2006-10-26 CN CN200680049966.8A patent/CN101370792B/zh active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1416423A (zh) *	2000-03-01	2003-05-07	阿斯特拉曾尼卡有限公司	用作抗肿瘤剂的2,4－二(杂－)芳基氨基(－氧基)－5－取代的嘧啶

Also Published As

Publication number	Publication date
ZA200804083B (en)	2009-09-30
UA109412C2 (uk)	2015-08-25
CN101370792A (zh)	2009-02-18
UA99899C2 (ru)	2012-10-25
UA109411C2 (uk)	2015-08-25

Legal Events

Date	Code	Title	Description
2009-02-18	C06	Publication
2009-02-18	PB01	Publication
2009-04-15	C10	Entry into substantive examination
2009-04-15	SE01	Entry into force of request for substantive examination
2013-03-20	C14	Grant of patent or utility model
2013-03-20	GR01	Patent grant
2019-05-28	TR01	Transfer of patent right
2019-05-28	TR01	Transfer of patent right	Effective date of registration: 20190508 Address after: American California Patentee after: Biomedical impact company Address before: American California Patentee before: Targegen Inc.
2019-09-03	CP02	Change in the address of a patent holder
2019-09-03	CP02	Change in the address of a patent holder	Address after: 86 Morris Street, Summit City, New Jersey, USA Patentee after: Biomedical impact company Address before: American California Patentee before: Biomedical impact company

Publication	Publication Date	Title
CN101370792B (zh)	2013-03-20	激酶的联-芳基间-嘧啶抑制剂
CN103626742A (zh)	2014-03-12	激酶的联-芳基间-嘧啶抑制剂
US8133900B2 (en)	2012-03-13	Use of bi-aryl meta-pyrimidine inhibitors of kinases
CN101155799A (zh)	2008-04-02	嘧啶化合物和使用方法
US8604042B2 (en)	2013-12-10	Bi-aryl meta-pyrimidine inhibitors of kinases
CN102317269A (zh)	2012-01-11	新氨基氮杂杂环甲酰胺类
JP6280912B2 (ja)	2018-02-14	複素環化合物
WO2016039408A1 (ja)	2016-03-17	複素環化合物
CN103298805A (zh)	2013-09-11	喹唑啉化合物及其使用方法
KR101971887B1 (ko)	2019-04-25	선택적 jak3 및/또는 jak1 키나아제 억제제로서 사용되는 방향족 헤테로고리 화합물의 제조 방법 및 방향족 헤테로고리 화합물의 용도
AU2012230091B2 (en)	2015-04-23	Bi-aryl meta-pyrimidine inhibitors of kinases
MX2008005810A (en)	2008-09-26	Bi-aryl meta-pyrimidine inhibitors of kinases